Dr Reddy's Laboratories has launched toripalimab, an immune oncology drug for adults with recurrent or metastatic nasopharyngeal carcinoma in India. This follows a licensing agreement with Shanghai Junshi Biosciences. Toripalimab is now available in India, making it the third country to access this treatment after China and the US.
